NCT07897630

Enrolling By InvitationPhase 3

Suprachoroidal Bevacizumab Versus Intravitreal Bevacizumab i...

Khyber Teaching Hospital Source

Khyber Teaching Hospital

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

485/IREB/KTH

Study Type

interventional

Estimated enrollment

60

Locations

1 country

Sites

1

Timeline

Study Start

October 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

October 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

December 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

Diabetic macular edema is an eye condition caused by diabetes in which fluid accumulates in the central part of the retina, leading to blurred vision and potentially permanent vision loss. Bevacizumab is a medicine that blocks vascular endothelial growth factor (VEGF), a protein involved in abnormal leakage from blood vessels. It is commonly used as an injection into the eye to treat this condition. This study aims to compare two methods of delivering bevacizumab in patients with center-involving diabetic macular edema. Participants will be randomly assigned to one of two groups. The first group will receive bevacizumab injections into the vitreous cavity of the eye (intravitreal injection), while the second group will receive injections into the space between the sclera and choroid of the eye (suprachoroidal injection). Both groups will receive injections once a month for three months. The study will compare changes in vision and central retinal thickness, measured using an eye examination and optical coherence tomography (OCT), from the start of the study to the four-month assessment. The occurrence of treatment-related complications and other adverse events will also be recorded. The study hypothesis is that suprachoroidal bevacizumab will provide improvements in vision and retinal thickness comparable to intravitreal bevacizumab, with a potentially different safety profile. The findings may help determine whether suprachoroidal delivery is a useful alternative to the established intravitreal route for treating diabetic macular edema.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: enrolling by invitation
Estimated enrollment: 60 participants
Study completion date: December 2027
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
September 15, 2026
Actual (reported)
Study Start
October 1, 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
First Posted
October 27, 2026
Actual (reported)
Primary Completion
October 2027
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2027
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: October 27, 2026
Status Verified: October 2026
Last Update Submitted: October 22, 2026

Conditions

Diabetic Macular Edema (DME)

Keywords

Diabetic Macular Edemaintravitreal BevacizumabSuprachoroidal Bevacizumab

Outcome Measures

Primary Outcomes (2)

Central Macular Thickness
Central Macular Thickness on Optical Coherence Tomography
3 months
Visual Acuity
Visual Acuity on LogMAR
3 months

Study Arms (2)

Suprachoroidal

EXPERIMENTAL

Suprachoroidal Bevacizumab Injection

Drug: Bevacizumab

Intravitreal

ACTIVE COMPARATOR

Intravitreal Bevacizumab Injection

Drug: Bevacizumab

Interventions

BevacizumabDrug

Bevacizumab

Suprachoroidal

BevacizumabDrug

Bevacizumab

Intravitreal

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

All patients with centre involving diabetic macular edema on OCT

You may not qualify if:

Sponsors & Collaborators

Khyber Teaching Hospital
Otherlead

Study Sites (1)

Khyber Teaching Hospital

Peshawar, KPK, 25000, Pakistan

MeSH Terms

Interventions

Bevacizumab

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Associate Professor

Study Record Dates

First Submitted

September 15, 2026

First Posted

October 27, 2026

Study Start

October 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

NCT07515079

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema

Phase 3Recruiting

NCT06882551

Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients

Phase 4Completed

NCT04739306

Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema

Phase 3Completed

NCT07338097

Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema

Not ApplicableEnrolling By Invitation

NCT07817121

A First-in-human Trial of SZN-8141 in Diabetic Macular Edema

Phase 1Not Yet Recruiting

NCT07457632

Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Using "Tauroursodeoxycholate" or Traditional Chinese Medicine.

Phase 2Withdrawn

PDR, corneal opacity, VMT, previous anti-VEGF treatment, previous PRP

Contact the study team to confirm eligibility.

October 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

December 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

October 27, 2026

Record last verified: 2026-10

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07897630
Data provider: ClinicalTrials.gov
Source updated: 2026-10-27
Normalization version: ctgov-2

Open registry record

Source retrieved: 2026-10-29 23:02:37 UTC

Documents

Study Protocol and Statistical Analysis Plan
ProtocolSAP2026-10-22

Locations

PK(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Study Arms (2)

Suprachoroidal

Intravitreal

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Design

Study Record Dates

Source record

Documents

Locations